<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="453">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 14, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01177397</url>
  </required_header>
  <id_info>
    <org_study_id>CC-223-ST-001</org_study_id>
    <nct_id>NCT01177397</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma</brief_title>
  <official_title>A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <authority>France: Direction Générale de la Santé</authority>
    <authority>France: French Data Protection Authority</authority>
    <authority>France: Haute Autorité de Santé Transparency Commission</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Ministry of Health</authority>
    <authority>France: Ministère de l'Enseignement supérieur et de la Recherche</authority>
    <authority>France: National Consultative Ethics Committee for Health and Life Sciences</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <authority>Spain: Departament de Salut de la Generalitat de Catalunya</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Spain: Ministry of Health and Consumption</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>United Kingdom: Department of Health</authority>
    <authority>United Kingdom: Food Standards Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: National Health Service</authority>
    <authority>United Kingdom: National Institute for Health Research</authority>
    <authority>United Kingdom: Research Councils UK</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this first human study with CC-223 is to assess the safety and action of
      a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors
      unresponsive to standard therapies and to determine the appropriate dose and tumor type for
      later-stage clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initially, patients will be treated with oral CC-223 for one month. During this time,
      various tests (involving blood and urine collections, ECGs, etc) will be performed. Those
      whose tumors stabilize or regress may continue receiving treatment for as long as they
      benefit from CC-223. Different dose levels of CC-223 will be tested in a dose-rising study
      design.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>From the time of informed consent, throughout dosing period and for 21 days after the last dose of CC-223</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the safety profile and dose-limiting toxicity of CC-223 using NCI CTCAE v4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Throughout the first cycle (30 days) through to the first day of Cycle 2.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Standard variables (eg. Cmax, AUC, half-life) to define the PK profile for single and multiple doses of oral CC-223.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Throughout the first cycle (30 days) through to the first day of Cycle 2.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Phosphorylation inhibition changes by levels of S6, 4EBP (for mTORC1) and AKT (for mTORC2) in circulating granulocytes, and tumor tissue (when available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Every 2-3 months until proof of tumor progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor response rates using appropriate objective criteria for various malignancies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Neuroendocrine Tumors of Non-Pancreatic Origin</condition>
  <condition>Hormone Receptor-Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CC-223</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive CC-223, but serial patient groups will receive different dose levels in Phase 1. The number of groups will be determined by the number of dose levels required to establish dose-limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223</intervention_name>
    <description>Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.</description>
    <arm_group_label>CC-223</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed advanced solid tumor, Non-Hodgkin Lymphoma or multiple
             myeloma

          -  Patients have not tolerated or progressed on standard therapy, and no further
             standard therapy is available

          -  Archival and screening tumor biopsy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (solid tumors), 0-2
             (hematologic malignancy)

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior systemic cancer-directed treatments or investigational drugs within 4 weeks or
             5 half lives, whichever is shorter, prior to starting study drug or who have not
             recovered from side effects of such therapy.  Subjects must have recovered from any
             effects of recent radiotherapy that might confound the safety evaluation of study
             drug

          -  Symptomatic brain metastases (prior Rx and stable metastases are OK)

          -  Acute or chronic liver or renal disease or pancreatitis

          -  Diarrhea ≥ Grade 2, impaired GI absorption

          -  Impaired cardiac function

          -  Diabetes requiring Rx, glucose &gt;126 mg/dL, HbA1c ≥6.5%

          -  Peripheral neuropathy ≥ Grade 2

          -  Pulmonary fibrosis

          -  Known HIV infection

          -  Known chronic hepatitis B or C virus (HBV/HCV) infection, unless comorbidity in
             subjects with HCC

          -  Pregnant, inadequate contraception

          -  Most concurrent second malignancies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen Hege, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center-Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Neuro-Oncology Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (SCRI)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy, Dept. of Medicine</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Oncologia Medica Sala de Investigación</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 23, 2015</lastchanged_date>
  <firstreceived_date>August 5, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid malignant neoplasms,Non-Hodgkin Lymphoma,</keyword>
  <keyword>Multiple Myeloma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apudoma</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
